Yang Li Biography and Net Worth

VP of Surrozen

Dr. Yang Li is the Executive Vice President of Research at Surrozen. Dr. Li is a distinguished scientist and a well-recognized leader in the Wnt field with over 90 high-impact publications and numerous patents. With over 25 years of experience in the biopharmaceutical industry, Dr. Li has a proven track record of advancing drug molecules from initial concept to clinical application.

His career is marked by successes in translating complex biological concepts into clinical-stage candidates. During his tenure as Scientific Director at Amgen, his leadership was instrumental in progressing various therapeutic programs into the clinic. Dr. Li’s academic foundation includes a Ph.D. in Cell Biology from Stanford University, as well as dual B.S. degrees in Chemistry and Molecular and Cell Biology from Pennsylvania State University.

What is Yang Li's net worth?: The estimated net worth of Yang Li is at least $537.44 thousand as of January 5th, 2026. Dr. Li owns 16,091 shares of Surrozen stock worth more than $537,439 as of April 30th. This net worth evaluation does not reflect any other assets that Dr. Li may own. Learn More about Yang Li's net worth.
How do I contact Yang Li?: The corporate mailing address for Dr. Li and other Surrozen executives is 1 PALMER SQUARE SUITE 305, PRINCETON NJ, 08540. Surrozen can also be reached via phone at 650-489-9000 and via email at [email protected]. Learn More on Yang Li's contact information.
Has Yang Li been buying or selling shares of Surrozen?: Yang Li has not been actively trading shares of Surrozen in the last ninety days. Most recently, Yang Li sold 1,118 shares of the business's stock in a transaction on Monday, January 5th. The shares were sold at an average price of $19.87, for a transaction totalling $22,214.66. Following the completion of the sale, the vice president now directly owns 16,091 shares of the company's stock, valued at $319,728.17. Learn More on Yang Li's trading history.
Who are Surrozen's active insiders?: Surrozen's insider roster includes Tim Kutzkey (Director), Yang Li (VP), and Charles Williams (COO). Learn More on Surrozen's active insiders.
Are insiders buying or selling shares of Surrozen?: During the last year, Surrozen insiders bought shares 28 times. They purchased a total of 1,033,505 shares worth more than $16,849,523.68. During the last year, insiders at the sold shares 2 times. They sold a total of 2,684 shares worth more than $53,331.08. The most recent insider tranaction occured on March, 24th when Major Shareholder Tcg Crossover Gp Ii, Llc bought 106,658 shares worth more than $2,633,386.02. Insiders at Surrozen own 31.7% of the company. Learn More about insider trades at Surrozen.
Information on this page was last updated on 3/24/2026.

Yang Li Insider Trading History at Surrozen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/5/2026	Sell	1,118	$19.87	$22,214.66	16,091
1/3/2025	Sell	843	$17.37	$14,642.91	13,345

Yang Li Buying and Selling Activity at Surrozen

Surrozen Company Overview

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

Today's Range

Now: $33.40

$30.79

$33.60

50 Day Range

MA: $28.02

$25.00

$33.03

2 Week Range

Now: $33.40

$5.90

$33.96

Volume

81,946 shs

Average Volume

113,538 shs

Market Capitalization

$383.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52